August 2023: Nam cancer metastaticus colorectalis (mCRC) cum fluoropyrimidine, oxaliplatina et irinotecan-substructus chemotherapyre, anti-VEGF biologico therapio, et si RAS agreste genus, anti-EGFR therapia, Cibus et medicamentum Administration approbavit, approbavit. trifluridine et tipiracil (LONSURF, Taiho Oncology, Inc.). LONSURF, medicinalis unius agentis, iam FDA approbationem ad hunc usum mense Septembri 2015 accepit.
In SOLIS (NCT04737187), randomised, pittacium apertum, multicenter, iudicium internationale comparans LONSURF cum bevacizumab cum uno agente LONSURF anno 492 aegros cum cancro metastatico colorectali, qui maximam duarum priorum chemotherapyarum diaetam acceperat et progressionem suae morbi ostendit vel intolerantia ad ultimum regimen, salus et virtus aestimata.
Overall survival (OS) and progression-free survival (PFS) were the key effectiveness outcome metrics. Patients assigned to the LONSURF plus bevacizumab arm of the trial showed a statistically significant OS improvement when compared to patients assigned to the LONSURF arm (Hazard ratio 0.61; 95% CI: 0.49, 0.77; 1-sided p0.001). The median OS for the LONSURF plus bevacizumab arm was 10.8 months (95% CI: 9.4, 11.8) and for the LONSURF arm was 7.5 months (95% CI: 6.3, 8.6). In the LONSURF plus bevacizumab arm, the median PFS was 5.6 months (95% CI: 4.5, 5.9), while in the LONSURF arm, it was 2.4 months (95% CI: 2.1, 3.2) (Hazard ratio: 0.44; 95% CI: 0.36, 0.54; 1-sided p0.001).
Neutropenia, anaemia, thrombocytopenia, lassitudo, nausea, aucta AST, aucta ALT, aucta phosphatas alcalina, sodium minutum, diarrhoea, molestia stomachi, et appetitus decrescentes sunt frequentissimi eventus latus aut laboratorium abnormitates pro LONSURF cum bevacizumab (20%).
Diebus 1 per 5 et dies 8 per 12 singulorum cycli 28 dierum, dosis LONSURF commendatur 35 mg/m2 ore sumpta bis quotidie cum cibo. Singula de dosis bevacizumab, praescribens consule informationes.
View plenam praescribens de LONSURF.
